Finally, since our results suggest that BCL-xL upregulation could be detrimental for HCC treatment with regorafenib, but probably also for other treatments that generate mitochondrial sensitization, such as sorafenib, we checked in the Human Protein ATLAS data [37] if BCL-xL expression could be associated with a worse prognosis in liver cancer (Figure 8E). Here, BCL2L1 is linked to liver cancer.